Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12–23 months in China

References

• Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107:373–80. doi:10.1179/2047773213Y.0000000119.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med. 2010;17:3–8. doi:10.1111/j.1708-8305.2010.00448.x.
   PubMed Web of Science ®Google Scholar
• Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15:967–78.
   PubMed Web of Science ®Google Scholar
• Safadi MA, Barros AP. Meningococcal conjugate vaccines: efficacy and new combinations. J Pediatr. 2006;82:S35–44. doi:10.2223/JPED.1495.
   Google Scholar
• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23:S274–9.
   PubMedGoogle Scholar
• Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The global meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• World Health Organization Western Pacific Region. China, 2014 [accessed 2018 Dec 24] http://www.wpro.who.int/immunization/documents/epi_country_poster_2014_chn.pdf.
   Google Scholar
• Kim DS, Kim MJ, Cha SH, Kim HM, Kim JH, Kim KN, et al. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. Int J Infect Dis. 2016;45:59–64. doi:10.1016/j.ijid.2016.02.010.
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19:142–64. doi:10.1128/CMR.19.1.142-164.2006.
   PubMed Web of Science ®Google Scholar
• Borrow R, Lee JS, Vázquez JA, Enwere G, Taha MK, Kamiya H, et al. Meningococcal disease in the Asia-Pacific region: findings and recommendations from the global meningococcal initiative. Vaccine. 2016;34:5855–62. doi:10.1016/j.vaccine.2016.10.022.
   PubMed Web of Science ®Google Scholar
• Li J, Shao Z, Liu G, Bai X, Borrow R, Chen M, et al. Meningococcal disease and control in China: findings and updates from the global meningococcal initiative (GMI). J Infect. 2018;76:429–37. doi:10.1016/j.jinf.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Noya F, McCormack D, Reynolds DL, Neame D, Oster P. Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children. Can J Infect Dis Med Microbiol. 2014;25:211–16. doi:10.1155/2014/237560.
   PubMed Web of Science ®Google Scholar
• Cutland CL, Nolan T, Halperin SA, Kurugol Z, Ahmed K, Perrett KP, et al. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine. 2018;36:1908–16. doi:10.1016/j.vaccine.2018.02.013.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis. 2001;184:377–80. doi:10.1086/322024.
   PubMed Web of Science ®Google Scholar
• Idoko OT, Okolo SN, Plikaytis B, Akinsola A, Viviani S, Borrow R, et al. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. Vaccine. 2014;32:4220–27. doi:10.1016/j.vaccine.2014.04.052.
   PubMed Web of Science ®Google Scholar
• Javadekar B, Ghosh A, Kompithra RZ, Awasthi S, Perminova O, Romanenko V, et al. Safety and immunogenicity of two doses of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in indian and russian children aged 9 to 17 months. Indian Pediatr. 2018;55:1050–55.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measlesmumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29:4274–84. doi:10.1016/j.vaccine.2011.03.043.
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29:4264–73. doi:10.1016/j.vaccine.2011.03.009.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Pace D. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix((R))): A review. Drugs. 2017;77:1881–96. doi:10.1007/s40265-017-0828-8.
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745–52. doi:10.1086/509619.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K, Miller E. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis. 2002;186:1353–57. doi:10.1086/344324.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–67. doi:10.1016/S0140-6736(04)16725-1.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8(12):1892–903. doi:10.4161/hv.22166.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34:e298–307. doi:10.1097/INF.0000000000000897.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Bmj. 2003;326:365–66. doi:10.1136/bmj.326.7385.365.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, Stapley L, England A, Findlow J, Miller, et al. MillerKinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154–59. doi:10.1128/CVI.00384-09.
   PubMed Web of Science ®Google Scholar
• Ishola DA, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19:1126–30. doi:10.1128/CVI.05655-11.
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R. What would be the best schedule for prevention of meningococcal disease in all ages? The UK experience. Paediatr Drugs. 2016;18:83–87. doi:10.1007/s40272-016-0169-1.
   PubMed Web of Science ®Google Scholar
• Bona G, Castiglia P, Zoppi G, de Martino M, Tasciotti A, D’Agostino D, Han L, Smolenov I. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers. Vaccine. 2016;34:3363–70. doi:10.1016/j.vaccine.2016.05.009.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nimenrix: assessment report (EMEA/H/C/002226/II/0049). 2016 [accessed 2016 Nov 10] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002226/WC500220577.pdf.
   Google Scholar
• Wu X, Cai XL, Li MQ, Li YP, Ma B, Yuan L, et al. Study on the safety and immunogenicity of a new home-made vaccine of freeze-dried group A/C meningococcal polysaccharide conjugate. J Appl Prev Med. 2015;21:152–55.
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23:2222–27. doi:10.1016/j.vaccine.2005.01.051.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568–73. doi:10.1128/IAI.69.3.1568-1573.2001.
   PubMed Web of Science ®Google Scholar
• Division of Microbiology and Infectious Diseases (DMID). Pediatric toxicitytables November 2007 Draft. 2007 [accessed 2019 Apr 2] https://www.niaid.nih.gov/sites/ default/files/dmidpedtox.pdf.
   Google Scholar